ASMB
Assembly Biosciences Inc (ASMB)
Healthcare • NASDAQ • $29.74-3.85%
- Symbol
- ASMB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $29.74
- Daily Change
- -3.85%
- Market Cap
- $472.65M
- Trailing P/E
- 371.75
- Forward P/E
- -12.87
- 52W High
- $39.71
- 52W Low
- $12.11
- Analyst Target
- $48.75
- Dividend Yield
- N/A
- Beta
- N/A
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an…
Company websiteResearch ASMB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.